Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -212.4%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $877M | $796M | $65M | $203M | $4.3B | $61.6B | $143.0B | $230.0B | $317.9B | $510.1B | — |
| Enterprise Value | $1.1B | $1.1B | $86M | $194M | $4.3B | $61.6B | $143.0B | $229.9B | $317.8B | $510.0B | — |
| P/E Ratio → | -0.48 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 240.99 | 218.79 | 15.15 | 111.49 | 27265.46 | 2370.69 | 5994.87 | 31519.68 | 1346949.25 | 1004084.47 | — |
| P/B Ratio | 28.19 | 36.47 | 0.66 | 0.60 | 591.81 | 4359.39 | 3877.54 | 3679.02 | 3403.53 | 8874.55 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 289.70 | 20.27 | 107.04 | 27332.24 | 2370.84 | 5994.98 | 31514.20 | 1346630.15 | 1003992.90 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -62.8% | -62.8% | 100.0% | 78.3% | -877.1% | -9.9% | -47.3% | -27.2% | -358.1% | -8.5% | 49.9% |
| Operating Margin | -1853.9% | -1853.9% | -6062.8% | -17550.0% | -14248.4% | -112.9% | -183.8% | -543.8% | -11913.1% | -5076.6% | -3034.8% |
| Net Profit Margin | -3492.3% | -3492.3% | -5898.4% | -14729.1% | -10758.6% | -112.4% | -188.0% | -542.9% | -11820.8% | -5114.2% | -3029.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -212.4% | -212.4% | -115.3% | -154.9% | -158.1% | -114.5% | -90.2% | -50.8% | -37.0% | -73.6% | -64.7% |
| ROA | -38.8% | -38.8% | -56.2% | -94.4% | -56.7% | -58.1% | -59.2% | -38.3% | -29.2% | -58.5% | -56.7% |
| ROIC | -25.3% | -25.3% | -86.2% | -137.5% | -93.5% | -76.5% | -106.3% | -146.6% | -145.2% | -203.0% | -237.0% |
| ROCE | -21.8% | -21.8% | -60.6% | -117.3% | -84.3% | -66.1% | -63.9% | -41.2% | -31.3% | -63.2% | -62.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 12.28 | 12.28 | 0.37 | 0.07 | 1.92 | 1.26 | 0.54 | 0.30 | 0.20 | 0.18 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 11.82 | 0.22 | -0.02 | 1.45 | 0.29 | 0.07 | -0.64 | -0.81 | -0.81 | -0.38 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.73 | -2.73 | -7.27 | -16.87 | -192.46 | -19.40 | -30.24 | -25.59 | -21.19 | -25719.00 | -2416.20 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.72 | 0.72 | 0.85 | 1.65 | 2.49 | 3.13 | 5.70 | 8.83 | 13.64 | 13.51 | 1.91 |
| Quick Ratio | 0.72 | 0.72 | 0.85 | 1.65 | 2.49 | 3.13 | 5.50 | 8.47 | 13.45 | 13.51 | 1.91 |
| Cash Ratio | 0.59 | 0.59 | 0.73 | 1.53 | 2.06 | 2.85 | 4.18 | 8.14 | 13.39 | 13.32 | 1.75 |
| Asset Turnover | — | 0.01 | 0.01 | 0.00 | 0.01 | 0.70 | 0.38 | 0.08 | 0.00 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | 25.40 | 3.58 | 0.82 | — | — |
| Days Sales Outstanding | — | 70.51 | 89.15 | 106.47 | — | — | 74.79 | 56.13 | 71.14 | 119.99 | 143.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $458M | $23M | $10M | $578M | $578M | $678M | $656M | $614M | $463M | $532M |
Critical liquidity and dilution
As reported in financial statements, CBUS trades at a P/S multiple of 240.99, a valuation that appears to price the company as a high-growth technology platform rather than a commercial enterprise, despite the underlying reality of declining revenue and persistent, deep-seated operating losses.
The extreme P/S ratio suggests that investors are assigning significant optionality to the RTDS platform, effectively ignoring the lack of a stable, recurring revenue base. This valuation level warrants caution, as it implies an aggressive growth trajectory that is not currently supported by the company's historical milestone-based revenue performance.
Based on CBUS's reported figures, ROIC has remained consistently negative, bottoming out at -62.6% in 2024Q3, which indicates that the company is currently destroying shareholder value rather than compounding it through its research-heavy trait development activities.
The inability to generate positive returns on invested capital reflects the structural disconnect between high R&D spending and the current lack of commercial-scale royalty streams. Investors should monitor whether the integration of the Calyxt merger can eventually improve capital efficiency, though current trends suggest a continued decay in returns.
According to recent SEC filings, the company's DSO has fluctuated wildly between 45 and 116 days, highlighting the unpredictable nature of milestone-based revenue collection and the resulting strain on the firm's ability to manage its working capital cycle effectively.
The high volatility in collection cycles suggests that CBUS lacks the leverage to dictate payment terms with its seed company partners. This inefficiency exacerbates the company's liquidity challenges, as cash inflows remain tied to irregular project milestones rather than a predictable, high-velocity commercial sales process.
As indicated by the company's financial disclosures, the D/E ratio surged to 12.28 in 2025Q4, a development that reflects a dangerous reliance on debt financing as the equity base has been significantly eroded by years of persistent, large-scale operating losses.
This leverage profile is particularly concerning given the company's negative interest coverage ratios, which suggest that debt service is becoming increasingly difficult to sustain. The reliance on debt in the absence of positive cash flow indicates a high risk of further dilutive equity raises to satisfy creditors.
Based on reported figures, the D/E ratio is a misleading metric for CBUS, as it obscures the company's true financial distress by failing to account for the rapid depletion of the equity base that characterizes this pre-commercial biotechnology business model.
Analysts should instead focus on 'months of runway' or cash-burn-to-liquidity ratios, which provide a more accurate picture of the firm's survival horizon. Relying on traditional leverage ratios in this context ignores the reality that the company's primary risk is not debt service, but rather the total exhaustion of its cash reserves.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CBUS stock.
Cibus, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Cibus, Inc.'s return on equity (ROE) is -212.4%. The historical average is -99.6%.
Based on historical data, Cibus, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cibus, Inc. has -62.8% gross margin and -1853.9% operating margin.